Back

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients With Tumors Harboring FGFR1/2/3/4 Alterations

  • Clinical Trial Information

    Trial Contact: Leffin, Melissa; El-Shami, Jessica; Spinelli, Jennifer

  • IRB No: APEC1621B

    Protocol Abbrev: APEC1621B

    Principal Investigator: Amy A Smith, MD

    Phase: Drug: Phase II

    Age Group: Adult;Pediatric

    Secondary Protocol No: APEC1621B

    Treatment: Drug: Erdafitinib; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study

    Therapies Involved: Chemotherapy

    ClinicalTrials.gov ID: NCT03210714

  • Objective

    To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with JNJ-42756493 (erdafitinib) with advanced solid tumors (including central nervous system [CNS] tumors), non-Hodgkin lymphomas or histiocytic disorders that harbor genetic alterations in the FGFR1/2/3/4 pathway

  • Key Eligibility

    Sexes Eligible for Study - All
    Ages - 12 Months to 21 Years (Child, Adult)
    Accepts Healthy Volunteers - No